Psy131 - Access to Orphan Drugs (Od) in Spain: Analysis of Nusinersen’s Case

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2705
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Mechanism of Coordinated Access to Orphan Drugs

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2012English

Psy135 - Access to Orphan Drugs – Regulation Within the European Law

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries

PLoS ONE
Multidisciplinary
2015English

Php114 - The Erratic and Long Access Journey of Orphan Drugs From Europe to Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Php325 - Orphan Drugs‘ Market Access Challenges in Europe From a German Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Determinants of Orphan Drugs Prices in France: A Regression Analysis

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2017English

PHP46 Market Uptake of Orphan Drugs – A European Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Psy60 - Orphan Versus Ultra-Orphan Drugs Prices in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Access to Chagas Disease Treatment in Non-Endemic Countries: The Case of Spain

The Lancet Global Health
Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy